Thirdly, STVNA provides substantial neuroprotection through cerebral perfusion-independent effects and in permanent MCAO models of stroke, unlike tirilazad (a perfusion-dependent neuroprotective agent) [27] and anti-intercellular adhesion molecule-1 antibody [28], which have only been proven effective in tMCAO. The gene discussed is ICAM1; the disease is Stroke.